As of 6 Nov 2026, Lotus Eye Hospital and Institute trades at 1300.4× trailing earnings, above the industry P/E of 47.7×, and the shares are 29% below their 52-week high. It earns ROCE of 1.0% and ROE of 0.1%, and sales grew 4.5% a year over 3 years while net profit fell 73%. Debt is 0.26× equity. It is a small-cap company with a market cap of ₹216 Cr, ranked 29th of 40 Medical Care Facilities companies by market cap; the shares fell 14% over the past year.
- ₹107.74
- ₹108.48
- ₹103.95
- ₹107.74
- 55.9K
Health check
- ReturnsBehind
−13.9% over a year, better than 2 of 7 peers.
- Price tagPricier
P/E 1300.4 vs industry 47.7.
- GrowthSlow
Sales +4.5%, profit −73.0% a year over 3 years.
- ProfitabilityWeak
ROCE 1.0% vs peer median 11.9%.
- Balance sheetStretched
Debt 0.26× equity, interest covered 0.9×.
- Red flags2 to check
Return on equity is low at 0.1%.
Small cap
Defensive
Key metrics
- Market cap
- ₹216 Cr
- Small cap
- P/E
- 1300.4
- Industry 47.7
- Price to book
- 3.68
- Peers 8.03
- Dividend yield
- 0.00%
- ROE
- 0.1%
- Peers 12.8%
- ROCE
- 1.0%
- Peers 11.9%
- Debt to equity
- 0.26
- Debt ₹16 Cr
- EPS (TTM)
- ₹0.08
- Face value ₹10
- OPM (TTM)
- 8.5%
- Net margin 0.3%
- Sales growth
- +26.2%
- Latest quarter vs a year ago
- Profit growth
- +12.6%
- Latest quarter vs a year ago
- Price to sales
- 3.78
- EV/EBITDA 50.1
Strengths and risks
Strengths
- Quarterly sales up 26.2% on a year ago.
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Return on equity is low at 0.1%.
- P/E of 1300.4 against an industry P/E of 47.7.
About Lotus Eye Hospital and Institute
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch-free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery;…
- Headquarters
- Coimbatore
- Employees
- 402
- Sector
- Healthcare
- ISIN
- INE947I01017
- Website
- lotuseye.org
Price range
- Avg volume (3M)
- 15K
- 1-year return
- minus 13.9%
- From 52-week high
- minus 29.2%
Peers · Medical Care Facilities
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSPApollo Hospitals Enterprise | 8,446.00 | plus 0.90% | 1,21,441 | 54.0 | 11.45 | 19.2% | 22.5% | 15.1% | 14.8% | 33.3% | 0.24% | plus 7.2% |
| MAXHEALTHMax Healthcare Institute | 934.00 | plus 0.21% | 90,909 | 66.1 | 8.03 | 12.6% | 12.8% | 26.8% | 22.4% | 9.3% | 0.21% | minus 18.1% |
| MANIPALHOSManipal Health Enterprises | 646.70 | minus 1.61% | 85,065 | 133.6 | 9.05 | 9.8% | 9.2% | 17.8% | – | – | 0.00% | minus 1.5% |
| ASTERDMAster DM Quality Care | 713.15 | minus 0.89% | 62,092 | 115.6 | 8.03 | 9.4% | 9.7% | 19.2% | 15.7% | −3.0% | 0.42% | plus 4.5% |
| FORTISFortis Healthcare | 766.90 | minus 6.45% | 57,898 | 55.3 | 5.52 | 11.9% | 11.1% | 22.4% | 13.3% | 20.9% | 0.12% | minus 19.6% |
| NHNarayana Hrudayalaya | 1,903.00 | minus 0.65% | 38,650 | 44.7 | 7.73 | 11.4% | 19.1% | 18.5% | 20.5% | 9.9% | 0.23% | plus 4.7% |
| MEDANTAGlobal Health | 1,387.60 | minus 0.15% | 37,264 | 60.4 | 8.63 | 15.0% | 15.2% | 20.9% | 17.2% | 19.5% | 0.04% | plus 11.2% |
| LOTUSEYELotus Eye Hospital and Institute | 104.03 | minus 3.44% | 216 | 1300.4 | 3.68 | – | 0.3% | 8.5% | 4.5% | −73.0% | 0.00% | minus 13.9% |
| Median of 7 peers | – | −0.65% | 62,092 | 60.4 | 8.03 | 11.9% | 12.8% | 19.2% | 16.5% | 14.7% | 0.21% | 4.5% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 13.5 | 13 | 13.5 | 13.6 | 17.1 | |
| 12 | 12.3 | 12.9 | 13.1 | 14.1 | |
| 1.5 | 0.8 | 0.7 | 0.5 | 2.9 | |
| 10.9% | 5.9% | 4.8% | 3.5% | 17.3% | |
| 0.2 | 0.3 | 0.2 | 0.5 | 0.2 | |
| 0.1 | 0.1 | 0.3 | 0.3 | 0.5 | |
| 0.8 | 0.8 | 1 | 1.1 | 1.6 | |
| 0 | 0 | 0 | −0 | −0 | |
| 0.7 | 0.1 | −0.4 | −0.5 | 1 | |
| 25.3% | −58.6% | 30.5% | 33.6% | 39.2% | |
| 0.5 | 0.1 | −0.3 | −0.3 | 0.6 | |
| 0.26 | 0.06 | -0.13 | -0.15 | 0.30 |
Profit & loss
- Sales CAGR 3Y
- +4.5%
- Profit CAGR 3Y
- −73.0%
- EPS CAGR 3Y
- −72.7%
- ROE
- 0.1%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 46 | 47.2 | 48.6 | 52.5 | |
| – | +2.7% | +2.9% | +8.0% | |
| 38.3 | 40.6 | 45 | 48.9 | |
| 7.7 | 6.6 | 3.6 | 3.6 | |
| 16.7% | 14.0% | 7.3% | 6.8% | |
| 1 | 1.2 | 1.2 | 0.9 | |
| 0.1 | 0.1 | 0.4 | 0.8 | |
| 3 | 3.7 | 3 | 3.7 | |
| −0 | 0 | 0 | −0 | |
| 5.7 | 4 | 1.4 | −0.1 | |
| 27.9% | 27.4% | 46.5% | 250.0% | |
| 4.1 | 2.9 | 0.7 | 0.1 | |
| – | minus 28.5% | minus 74.6% | minus 89.1% | |
| 1.96 | 1.40 | 0.36 | 0.04 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 20.8 | 20.8 | 20.8 | 20.8 | |
| 36.8 | 38.6 | 39.2 | 39.3 | |
| 0.7 | 1.1 | 3.4 | 15.8 | |
| 4.9 | 6.1 | 6.1 | 6.6 | |
| 63.2 | 66.6 | 69.6 | 82.6 | |
| 44.1 | 48.7 | 53.9 | 65.7 | |
| – | 0.1 | – | 0.1 | |
| 1 | 2.4 | 2.4 | 2.5 | |
| 8.3 | 6.9 | 4 | 3.7 | |
| 9.8 | 8.6 | 9.3 | 10.6 | |
| 63.2 | 66.6 | 69.6 | 82.6 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 4.4 | 5.7 | 2.7 | 3 | |
| −2.2 | −3.7 | −4 | −12.4 | |
| −1.7 | −3.4 | −1.6 | 9 | |
| 0.5 | −1.4 | −2.9 | −0.3 | |
| −3.1 | −5.6 | −4.8 | −13 | |
| 1.3 | 0 | −2.1 | −10 | |
| −1 | −1 | −0 | −0 |
Shareholding pattern
- Promoters40.14%
- Public59.86%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 40.14% | 59.86% | 0.00 | |
| 30 Jun 2026 | 40.14% | 59.86% | 0.00 | |
| 31 Mar 2026 | 40.14% | 59.86% | plus 0.47 | |
| 31 Dec 2025 | 39.67% | 60.33% | minus 0.97 | |
| 30 Sep 2025 | 40.64% | 59.36% | – |
Major shareholders
Filings & events
News
No recent news coverage found.